Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. (INBP) files a range of documents with the U.S. Securities and Exchange Commission that provide insight into its business of manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products. These SEC filings include current reports on Form 8-K, annual reports on Form 10-K referenced in proxy materials, and definitive proxy statements on Schedule 14A.
For INBP, Form 8-K filings frequently report financial results for specific quarters and fiscal years under Item 2.02 (Results of Operations and Financial Condition). These filings typically furnish an earnings press release as an exhibit, summarizing revenue, operating income or loss, net income or loss and related per-share data, along with commentary on revenue concentration in the Contract Manufacturing Segment and performance of the nutraceutical business.
The company’s definitive proxy statement (DEF 14A) describes corporate governance and stockholder voting matters, including the election of a Class III director for a three-year term, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor for a specified fiscal year. It also explains record dates, voting procedures and quorum requirements for the annual meeting of stockholders.
Form 8-K filings related to the annual meeting disclose final voting results for director elections, advisory compensation proposals, advisory frequency of vote on executive compensation and auditor ratification. Together, these filings allow investors to review Integrated BioPharma’s financial reporting, governance structure and stockholder decisions.
On this page, SEC filings for INBP are updated from EDGAR as they become available. AI-powered tools can help summarize lengthy documents, highlight key items such as revenue trends, customer concentration in the Contract Manufacturing Segment, and outcomes of stockholder votes, and make it easier to interpret the implications of the company’s 10-K, 8-K and proxy disclosures.
Integrated Biopharma, Inc. furnished an earnings press release for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and provides the company’s quarterly financial results.
The information was furnished under Item 2.02 and, along with Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists the exhibit index and confirms the materials are provided via Inline XBRL.
Integrated BioPharma (INBP) reported lower quarterly results for the three months ended September 30, 2025. Sales, net were $12,689 (down 6.8% year over year), and gross profit was $1,019 versus $1,371 a year ago as cost of sales rose to 92.0% of sales. Operating income fell to $163 from $490, and net income was $123 compared with $259 in the prior-year quarter.
Customer concentration remained high: two contract manufacturing customers represented 87% of consolidated net sales, with Life Extension at 71% and Herbalife at 20% of segment sales. Operating cash flow improved to $1,301 from $657, lifting cash to $4,732. Working capital was approximately $14,860.
The company had no borrowings and access to a revolving credit facility and a convertible equipment line totaling about $4,500. Management cited inflation and tight labor markets as margin headwinds while keeping selling and administrative expenses near flat.
Integrated BioPharma, Inc. (INBP) filed its definitive proxy and set the 2025 Annual Meeting for December 1, 2025 at 9:00 a.m. local time at its Hillside, NJ offices. Stockholders will vote on: (1) electing Class III director nominee Eric Friedman for a three-year term; (2) a non-binding advisory vote on executive compensation (say‑on‑pay); (3) a non-binding advisory vote on the frequency of say‑on‑pay; and (4) ratifying CBIZ CPAs P.C. as independent auditor for the fiscal year ending June 30, 2026.
The Board unanimously recommends FOR the director nominee, FOR say‑on‑pay, THREE YEARS for say‑on‑pay frequency, and FOR auditor ratification. Holders of record as of October 17, 2025 may vote; 31,059,610 shares of common stock were outstanding on the record date. Proxy materials are available at materials.proxyvote.com/45811V.
Integrated Biopharma, Inc. filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The company clarifies the furnished information is not "filed" for Section 18 liability purposes and has attached the exhibit in Item 9.01.
Integrated BioPharma, Inc. (INBP) reports consolidated fiscal-year information and disclosures for the year ended June 30, 2025. The company states it has a cybersecurity program based on recognized standards and is not aware of any cybersecurity incidents that have materially affected its business. The balance sheet notes 50,000,000 shares authorized and roughly 31.1 million shares outstanding reported in the filing. The company recorded a $20 allowance for credit losses at June 30, 2025 (versus $1 at June 30, 2024). Two customers accounted for approximately 84% of consolidated net sales in 2025 and represented about 76% of accounts receivable at June 30, 2025. The filing discloses federal and state NOLs with limited realizability and a valuation allowance changes: a $830 reserve recorded against federal NOL-related deferred tax assets and a $347 release of the state NOL valuation reserve due to tax law change. Lease amendments and stock option plan details (plans with 4,659,652 shares remaining; recent option grants and exercise prices) are included, and a finance lease obligation of $485 due to a related party is disclosed.